Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 11, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 15, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001903669-25-000008
Filed / recorded
Dec 15, 2025, 11:52 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
SPRUCE BIOSCIENCES, INC.
Issuer CIK
1683553
Ticker
SPRB
Reporting person
Javier B. Szwarcberg
Relationship
Director, Officer
Officer title
CHIEF EXECUTIVE OFFICER
Security
Employee Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Dec 11, 2025
Transaction code
A
Shares / units
10,000
Acquired / disposed
Acquired (A)
Shares owned after
10,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.
The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan).